Ignite Creation Date:
2024-05-06 @ 6:27 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05660018
Status:
RECRUITING
Last Update Posted:
2023-04-04
First Post:
2022-12-02
Brief Title:
TMS Related Biomarker Assessments
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
TMS Related Biomarker Assessments
Status:
RECRUITING
Status Verified Date:
2023-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with schizophrenia spectrum disorder SSD will be exposed to active and sham repetitive transcranial magnetic stimulation rTMS in separate sessions SSD-related biomarkers will be assessed before and after the rTMS administration
Detailed Description:
Electrical neural oscillations of the brain can be measured at many levels ranging from single cell to local field potentials in animals to large-scale synchronized activities in the human scalp New evidence suggests that there may be common underlying abnormalities in oscillatory activities that are associated with schizophrenia-related cognitive and functional impairments There is currently no treatment for these electrical oscillation dysfunctions Transcranial magnetic stimulation TMS provides a non-invasive means for altering brain electrical neural activity TMS has been approved by FDA for the treatment of depression and many other mental disorders It has been used in a wide range of clinical research especially in neurology and psychiatry The investigators aim to develop TMS paradigms that will modulate brain responses during basic sensory to more complex cognitive performance and determine the parameters in anatomic locations and TMS modalities that may effectively and safely modulate neural activities If the current experiments successfully identified TMS methodsparadigms that improve neural oscillation and cognitive performances in schizophrenia patients in the future not part of the current protocol the investigators can then develop specific TMS treatment that may correct abnormal brain function and improve cognition and clinical symptoms of schizophrenia
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
True
Is an Unapproved Device?:
True
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None